CAR T cells’ variable regions are directed against a tumor target of interest, most often CD19 for B-lineage lymphomas and leukemias and more recently B cell maturation antigen (BCMA) for multiple myeloma [9,10,11]. This evidence concerns the gene TNFRSF17 and neoplasm.